Catalent Pharma Solutions (Stand 3G10), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced that it has won the ‘Innovation in Process and Formulation Development’ category at the annual CPhI Pharma Awards, for its OptiShell™ softgel technology platform.

Somerset, NJ and Madrid, Spain (PRWEB) October 14, 2015

Catalent Pharma Solutions (Stand 3G10), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced that it has won the ‘Innovation in Process and Formulation Development’ category at the annual CPhI Pharma Awards, for its OptiShell™ softgel technology platform.

Softgel capsules have long been recognized by the pharmaceutical community and patients as effective dosage forms for oral drug delivery. Softgels traditionally use gelatin as the film-forming polymer in the capsule shell. The OptiShell softgel technology uses plant-derived polysaccharides providing scientists with new formulation opportunities.

The different physico-chemical and thermo-mechanical properties of OptiShell capsules allow for encapsulation of a wider range of fill formulation types including semi-solids formulated at higher temperatures.

Catalent’s OptiShell technology was one of three finalists selected by a panel of pharma industry experts, and the award was presented at a ceremony on October 13th, at the world’s largest pharmaceutical event, CPhI Worldwide, which is currently taking place at Feria de Madrid, Spain.

“We would like to thank the judging panel for their recognition of our OptiShell softgel platform,” commented Dr. Aris Gennadios, Catalent’s President of Softgel Technologies. “OptiShell technology may provide an opportunity for formulators to develop semi-solid, extended release formulations with improved and more consistent therapeutic effectiveness. The “hot-filling” process enables delivery of semi-solid formulations in a patient preferred dose form, while the semi-solid matrix offers extended release profiles that can reduce the maximum API concentration in the bloodstream, decrease the dosing frequency, and, therefore, potentially increase patient adherence.”

For further information or to arrange a meeting with a member of the executive team during the show, please contact Richard Kerns at richard(at)nepr(dot)eu

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

advertisement | advertise on newsday

For the original version on PRWeb visit: http://www.prweb.com/releases/2015/10/prweb13022083.htm